Matches in SemOpenAlex for { <https://semopenalex.org/work/W2123297860> ?p ?o ?g. }
Showing items 1 to 66 of
66
with 100 items per page.
- W2123297860 endingPage "358" @default.
- W2123297860 startingPage "358" @default.
- W2123297860 abstract "Combination therapy of inhaled corticosteroid/long acting β2-agonist (ICS/LABA) is the cornerstone of managing asthmatics who are uncontrolled with low-medium dose of ICS. The novel ICS/LABA combination of fluticasone propionate and formoterol (flu/form) provides potent anti-inflammatory and rapid bronchodilatory effect.This randomized, multi-centre, double-blind study compared the efficacy and safety of flu/form (125/6 mcg BD; Maxiflo®) with the well-established budesonide/formoterol combination (bud/form 200/6 mcg BD), both delivered through a pressurized metered dose inhaler (pMDI) in patients with moderate to severe persistent asthma over 12 weeks.This study enrolled patients between 18 and 65 years. The primary end-point was to demonstrate non-inferiority for the mean change in the pre-dose morning peak expiratory flow values (PEF). The secondary end-points included lung function assessments, number of symptom-free days and nights, rescue medication use, day-and night-time symptom scores and safety evaluation.Two hundred and thirty-two patients were randomized to either flu/form (n = 117) or bud/form (n = 115). At the end of 12 weeks, flu/form was non-inferior to bud/form with regards to the primary end-point of morning PEF (48.07 L/min vs. 49.03 L/min, p > 0.05). These improvements were statistically significant (p < 0.0001) vs baseline. Similar improvements were observed between the two groups for secondary efficacy end-points including FEV1, symptom-free nights, rescue medication use, day-and night-time symptom scores (p > 0.05). Flu/form exhibited a safety profile comparable to that of bud/form.Fluticasone/formoterol combination administered through a pMDI is as efficacious and well-tolerated as budesonide/formoterol and offers a new therapeutic option for patients with moderate to severe persistent asthma." @default.
- W2123297860 created "2016-06-24" @default.
- W2123297860 creator A5034571205 @default.
- W2123297860 creator A5075507836 @default.
- W2123297860 date "2002-01-01" @default.
- W2123297860 modified "2023-10-14" @default.
- W2123297860 title "Vacunación frente a la hepatitis B en pacientes inmunocomprometidos" @default.
- W2123297860 cites W1969522179 @default.
- W2123297860 cites W1973795001 @default.
- W2123297860 cites W2022932565 @default.
- W2123297860 cites W2056524016 @default.
- W2123297860 cites W2081765996 @default.
- W2123297860 cites W2171288178 @default.
- W2123297860 doi "https://doi.org/10.1016/s0025-7753(02)73415-5" @default.
- W2123297860 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/12356372" @default.
- W2123297860 hasPublicationYear "2002" @default.
- W2123297860 type Work @default.
- W2123297860 sameAs 2123297860 @default.
- W2123297860 citedByCount "0" @default.
- W2123297860 crossrefType "journal-article" @default.
- W2123297860 hasAuthorship W2123297860A5034571205 @default.
- W2123297860 hasAuthorship W2123297860A5075507836 @default.
- W2123297860 hasConcept C126322002 @default.
- W2123297860 hasConcept C19720800 @default.
- W2123297860 hasConcept C2776042228 @default.
- W2123297860 hasConcept C2776136866 @default.
- W2123297860 hasConcept C2776804153 @default.
- W2123297860 hasConcept C2779028295 @default.
- W2123297860 hasConcept C2779871671 @default.
- W2123297860 hasConcept C2780261241 @default.
- W2123297860 hasConcept C2781212218 @default.
- W2123297860 hasConcept C42219234 @default.
- W2123297860 hasConcept C71924100 @default.
- W2123297860 hasConceptScore W2123297860C126322002 @default.
- W2123297860 hasConceptScore W2123297860C19720800 @default.
- W2123297860 hasConceptScore W2123297860C2776042228 @default.
- W2123297860 hasConceptScore W2123297860C2776136866 @default.
- W2123297860 hasConceptScore W2123297860C2776804153 @default.
- W2123297860 hasConceptScore W2123297860C2779028295 @default.
- W2123297860 hasConceptScore W2123297860C2779871671 @default.
- W2123297860 hasConceptScore W2123297860C2780261241 @default.
- W2123297860 hasConceptScore W2123297860C2781212218 @default.
- W2123297860 hasConceptScore W2123297860C42219234 @default.
- W2123297860 hasConceptScore W2123297860C71924100 @default.
- W2123297860 hasIssue "9" @default.
- W2123297860 hasLocation W21232978601 @default.
- W2123297860 hasLocation W21232978602 @default.
- W2123297860 hasOpenAccess W2123297860 @default.
- W2123297860 hasPrimaryLocation W21232978601 @default.
- W2123297860 hasRelatedWork W1989310269 @default.
- W2123297860 hasRelatedWork W2005698822 @default.
- W2123297860 hasRelatedWork W2024265404 @default.
- W2123297860 hasRelatedWork W2056638681 @default.
- W2123297860 hasRelatedWork W2155217850 @default.
- W2123297860 hasRelatedWork W2313479281 @default.
- W2123297860 hasRelatedWork W2332556071 @default.
- W2123297860 hasRelatedWork W2621439852 @default.
- W2123297860 hasRelatedWork W2752966097 @default.
- W2123297860 hasRelatedWork W2989972503 @default.
- W2123297860 hasVolume "119" @default.
- W2123297860 isParatext "false" @default.
- W2123297860 isRetracted "false" @default.
- W2123297860 magId "2123297860" @default.
- W2123297860 workType "article" @default.